Catalyst Pharmaceutical Partners, Inc. Form 4 September 20, 2007

September 20	5, 2007									
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION							OMB APPROVAL			
Washington, D.C. 20549							OMB Number:	3235-0287		
Check thi if no long	er							Expires:	January 31, 2005	
subject to Section 10 Form 4 or	6. SECURITIES							Estimated a burden hou response	average rs per	
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type R	Responses)									
WALLACE MILTON J Syn			2. Issuer Name and Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer			
			Catalyst Pharmaceutical Partners, Inc. [CPRX]				(Check all applicable)			
			ate of Earliest Transaction onth/Day/Year)			X_ Director 10% Owner Officer (give title Other (specify below) below)				
220 MIRAC	/10/2007									
			nendment, Date Original Ionth/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
CORAL GA	BLES, FL 33134						Form filed by M Person	Nore than One Re	porting	
(City)	(State) (Zip) T	able I - Non-E	erivative	Securi	ities Acc	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Code	4. Securi on(A) or D (D) (Instr. 3,	ispose	d of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	09/10/2007		Code V P	Amount 5,000	(D) A	Price \$ 3.94	305,000	D (1)		
Common Stock							29,184	I	See Note (1)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Catalyst Pharmaceutical Partners, Inc. - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Other				
WALLACE MILTON J 220 MIRACLE MILE, SU CORAL GABLES, FL 331	Х							
Signatures								
/s/ Milton J. Wallace	09/20/2007							
<pre>**Signature of Reporting Person</pre>	Date							
Explanation of Responses:								
* If the form is filed by more	than one rep	orting perso	on, see Instruct	ion 4(b)(v)				

- i die totin is fred by more data one reporting person, see instruction ((b)()).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The securities acquired are owned beneficially with his wife, Patricia Wallace. Following this purchase, Reporting Person directly owns beneficially: (i) 294,546 shares with his wife, Patricia Wallace, and (ii) 10,454 shares through his Individual Retirement Account. Reporting Person also reports beneficial ownership of 29,184 shares of the Company's common stock that are owned of record by

 Reporting reison also reports beneficial ownership of 29,194 shares of the Company's common stock that are owned of record by Biscayne National Corp. (Reporting Person is the President and majority shareholder of Biscayne National Corp). While Reporting Person owns the shares held by Biscayne National Corp. for Section 13(d) purposes, he disclaims beneficial ownership for Section 16(b) purposes except to the extent of his pecuniary interest in such shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.